Jasper Therapeutics, Inc.
JSPR
$0.72
$0.022.35%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 89.67% | 94.47% | 62.58% | -0.53% | -83.25% |
| Total Depreciation and Amortization | -91.86% | -92.47% | 18.37% | -57.67% | -13.71% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -351.69% | -550.70% | -258.38% | -20.16% | 33.21% |
| Change in Net Operating Assets | -86.58% | -12.33% | -1,255.58% | -109.73% | 786.03% |
| Cash from Operations | 55.23% | 36.31% | -3.47% | -20.97% | -32.30% |
| Capital Expenditure | -- | -- | 100.00% | 100.00% | 95.54% |
| Sale of Property, Plant, and Equipment | 900.00% | -- | -100.00% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 7,900.00% | -- | 100.00% | 100.00% | 100.64% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.85% | -- | -- | 315,322.22% | 3,304.97% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.85% | -- | -198.55% | 315,322.22% | 3,304.97% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 26.47% | 36.30% | -6.43% | 179.55% | 20.31% |